← Browse by Condition
Medical Condition

renal cell carcinoma rcc

Total Trials
6
Recruiting Now
6
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for renal cell carcinoma rcc sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — renal cell carcinoma rcc Clinical Trials

How many clinical trials are currently recruiting for renal cell carcinoma rcc?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for renal cell carcinoma rcc, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for renal cell carcinoma rcc?
renal cell carcinoma rcc research spans Phase 1 (3 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a renal cell carcinoma rcc clinical trial?
Eligibility criteria for renal cell carcinoma rcc trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Phase 2
3
Top Sponsors
GI Innovation, Inc. 2 trials
Compass Therapeutics 1 trial
Peking University Third Hospital 1 trial
The Affiliated Hospital of Qingdao University 1 trial
Jinling Hospital, China 1 trial

Recruiting Clinical Trials

NCT07172802 Phase 1, Phase 2
Recruiting
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Enrollment
76 pts
Location
South Korea
Sponsor
GI Innovation, Inc.
View Trial →
NCT07419841 Phase 1
Recruiting
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Enrollment
70 pts
Location
United States
Sponsor
Compass Therapeutics
View Trial →
NCT05824975 Phase 1, Phase 2
Recruiting
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Enrollment
358 pts
Location
United States, South...
Sponsor
GI Innovation, Inc.
View Trial →
NCT07117227
Recruiting
Validation of RCC Predicting Model With Emulated-target Trial
Enrollment
4,700 pts
Location
China
Sponsor
Peking University Third Hospit...
View Trial →
NCT06916624
Recruiting
Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma
Enrollment
40 pts
Location
China
Sponsor
The Affiliated Hospital of Qin...
View Trial →
NCT07175480 Phase 2
Recruiting
PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk
Enrollment
30 pts
Location
China
Sponsor
Jinling Hospital, China
View Trial →

Related Conditions

advanced solid tumor (2) metastatic solid tumor (2) hepatocellular carcinoma hcc (2) non small cell lung cancer nsclc (1) head and neck hnscc (1) pancreatic cancer (1) gastroesophageal cancer gc (1) endometrial cancer (1) soft tissue sarcoma sts (1) platinum resistant ovarian cancer proc (1) colorectal cancer crc (1) her2 negative breast cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology